Article
Oncology
Jomjit Chantharasamee, Karlton Wong, Pasathorn Potivongsajarn, Amir Qorbani, Neda Motamed, Sandra Brackert, Joshua Cohen, Bartosz Chmielowski, Anusha Kalbasi, Jianyu Rao, Scott Nelson, Arun Singh
Summary: There is currently no standard adjuvant treatment protocol for localized uterine leiomyosarcoma (uLMS). This study aims to determine the benefit of adjuvant chemotherapy for uLMS. The results showed that patients who received any form of adjuvant therapy had a slightly longer disease-free survival, but the difference was not significant. Tumor size and mitotic rate were identified as independent prognostic factors for worse outcomes. Therefore, the need for adjuvant therapy for resected uLMS remains in question.
Article
Oncology
Dimitrios Nasioudis, Nawar A. Latif, Emily M. Ko, Lori Cory, Sarah H. Kim, Lainie Martin, Fiona Simpkins, Robert Giuntoli II
Summary: This study investigated the incidence of homologous recombination DNA damage response (HR-DDR) genomic alterations in patients with uterine sarcoma. The results showed that approximately one in three patients with uterine sarcoma carry pathogenic alterations in HR-DDR genes, with the highest incidence observed in patients with uterine leiomyosarcoma and adenosarcoma.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
R. J. Edmondson, R. L. O'Connell, S. Banerjee, L. Mileshkin, P. Sykes, P. Beale, A. Fisher, A. Bonaventura, D. Millan, S. Nottley, C. Benson, A. Hamilton, K. Sjoquist, L. Alexander, C. Kelly, K. Carty, L. Divers, N. Bradshaw, M. Friedlander
Summary: Anastrozole shows clinical benefit in treating patients with uterine leiomyosarcomas and carcinosarcomas, especially in a subset of patients with good tolerance. However, the objective response rates are relatively low.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Alexandra Diggs, Tiffany Y. Sia, Yongmei Huang, Allison Gockley, Alexander Melamed, Fady Khoury-Collado, Caryn St. Clair, June Y. Hou, Dawn L. Hershman, Jason D. Wright
Summary: This study analyzed the utilization of adjuvant chemotherapy and radiation therapy in patients with stage II and III uterine leiomyosarcoma (uLMS). The results showed that the use of chemotherapy is increasing while the use of radiation therapy is decreasing. Radiation therapy is associated with improved survival in both stage II and III disease, but there is no association between adjuvant chemotherapy and survival in stage II patients.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Obstetrics & Gynecology
Ali Ayhan, Mehmet Tunc, Nurettin Boran, Ghanim Khatib, Mehmet Gokcu, Tayup Simsek, Ozlem Isiksacan Ozen, Tayfun Toptas, Ibrahim Yalcin, Mehmet Mutlu Meydanli
Summary: Comparative study showed that UUS has a significantly poorer DFS than HGESS, while there was no significant difference in OS between the two groups. LVSI was the sole significant prognostic factor for HGESS, while no significant independent factor was found for UUS.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS
(2021)
Article
Oncology
Sabrina Croce, Mojgan Devouassoux-Shisheboran, Patricia Pautier, Isabelle Ray-Coquard, Isabelle Treilleux, Agnes Neuville, Laurent Arnould, Pierre-Alexandre Just, Marie Aude Le Frere Belda, Gerlinde Averous, Agnes Leroux, Eliane Mery, Delphine Loussouarn, Nicolas Weinbreck, Sophie Le Guellec, Florence Mishellany, Philippe Morice, Frederic Guyon, Catherine Genestie
Summary: The landscape of uterine sarcomas is becoming more complex with the discovery of new entities and molecular alterations. Uterine sarcomas can be categorized into complex genomic and simple genomic types. Different subtypes of uterine sarcomas have distinct characteristics and clinical outcomes. Accurate diagnosis and treatment of uterine sarcomas require a combination of morphology, immunohistochemistry, and molecular data.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Pluvio J. Coronado, Maria Alonso-Espias, Yusuf Yildirim, Ronalds Macuks, Rosanna Mancari, Patriciu Achimas-Cadariu, Silvana M. Aniorte, Marco Mitidieri, Eric Lambaudie, Nathanael Dubois, Ignacio Zapardiel, SARCUT Study Grp
Summary: This study aimed to assess the impact of lymph node dissection (LND) on disease-free survival (DFS) and overall survival (OS) in women surgically treated for uterine leiomyosarcoma (ULMS). The results showed a significant difference in 5-year DFS between patients who underwent LND and those who did not, but no significant difference in 5-year OS. In conclusion, LND has no impact on DFS and OS in patients with ULMS.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
S. Cabrera, V. Bebia, U. Acosta, S. Franco-Camps, L. Manalich, A. Garcia-Jimenez, A. Gil-Moreno
Summary: A retrospective study on ESS and USS patients showed higher survival rates in LG-ESS cohort and adjuvant radiotherapy correlated with improved survival in HG-ESS and UUS patients. Age, FIGO stage, surgical quality and histological type were significantly correlated with survival in the global cohort.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2021)
Article
Medicine, General & Internal
Leonardo Tomiatti da Costa, Laura Gonzalez dos Anjos, Luciane Tsukamoto Kagohara, Giovana Tardin Torrezan, Claudia A. Andrade De Paula, Edmund Chada Baracat, Dirce Maria Carraro, Katia Candido Carvalho
Summary: This study investigated genetic mutations in uterine sarcomas and carcinosarcomas, identifying common mutations in TP53, ATM, and PIK3CA. Different tumor subtypes showed distinct mutation patterns, suggesting potential for precision medicine-based treatment approaches.
Article
Oncology
Maria Danieli, Francesco Barretta, Stefano Radaelli, Marco Fiore, Claudia Sangalli, Marta Barisella, Elena Palassini, Rosalba Miceli, Anna Maria Frezza, Dario Callegaro, Paola Collini, Paolo Giovanni Casali, Silvia Stacchiotti, Alessandro Gronchi
Summary: This study explored the correlation between pathological and radiological response to preoperative treatments and outcome in surgically treated patients with myxofibrosarcoma and undifferentiated pleomorphic sarcoma. The results showed that the percentage of visible residual tumor had a greater impact on survival and disease-free survival than the size reduction of the tumor, especially in patients receiving neoadjuvant chemotherapy or radiotherapy.
Review
Oncology
Blair Mcnamara, Levent Mutlu, Michelle Greenman, Justin Harold, Alessandro Santin
Summary: Uterine serous carcinoma (USC) and uterine carcinosarcoma (UCS) are rare and aggressive forms of uterine cancer, with specific mutations that can be targeted by HER2-targeting therapies. This article summarizes the evidence and ongoing clinical trials for these targeted therapies.
Article
Medicine, General & Internal
Milos Pantelic, Ljiljana Gvozdenovic, Milana Panjkovic, Marko Stojic, Dragan Stajic, Aleksandra Petric, Sonja Pop Trajkovic, Milan Trenkic, Dusan Simic, Lazar Zivadinovic, Aleksandar Zivadinovic
Summary: This study summarizes the clinical and pathological characteristics of an undifferentiated uterine sarcoma case, which is an aggressive malignant tumor with a poor prognosis.
Review
Oncology
Jose Alejandro Perez-Fidalgo, Eugenia Ortega, Jordi Ponce, Andres Redondo, Isabel Sevilla, Claudia Valverde, Josep Isern Verdum, Enrique de Alava, Mar Galera Lopez, Gloria Marquina, Ana Sebio
Summary: Uterine sarcomas are rare and diverse, making diagnosis, surgical management, and systemic treatment challenging; treatment decisions should involve a multidisciplinary tumor board; evidence is limited, often based on case series or clinical trials including these tumors with other soft tissue sarcomas. These guidelines summarize the relevant evidence on the diagnosis, staging, pathological disparities, surgical management, systemic treatment, and follow-up of uterine sarcomas.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Oncology
Chujie Bai, Lu Zhang, Yaohui Wang, Xia You, Yongzhi Ju, Tingting Sun, Zhengfu Fan
Summary: Undifferentiated high-grade pleomorphic sarcoma (UHPS) is a rare and aggressive soft tissue sarcoma. NTRK fusions are commonly found in UHPS and targeted therapy has shown positive response.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Takuma Hayashi, Kenji Sano, Nobuo Yaegashi, Kaoru Abiko, Ikuo Konishi
Summary: Uterine leiomyoma develops from smooth muscle tissue, while uterine sarcoma can develop from smooth muscle tissue or stroma. Uterine sarcoma is classified into three types: leiomyosarcoma, endometrial stromal sarcoma (ESS), and carcinosarcoma. Although both leiomyosarcoma and ESS are classified as uterine sarcoma, they differ in terms of their sites of occurrence, symptoms, and treatment methods.
CURRENT ISSUES IN MOLECULAR BIOLOGY
(2023)
Article
Obstetrics & Gynecology
Anna Collins, Annie Jacob, Esther Moss
Summary: This article reviews the current evidence on minimally-invasive surgery in high-risk endometrial cancer patients and identifies areas that require further research.
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY
(2024)
Editorial Material
Obstetrics & Gynecology
Thomas D'Hooghe
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY
(2024)
Editorial Material
Obstetrics & Gynecology
Thomas M. D'Hooghe
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY
(2024)
Article
Obstetrics & Gynecology
Lina Youssef, Lea Testa, Francesca Crovetto, Fatima Crispi
Summary: Preeclampsia is a pregnancy-specific disease with an unknown precise cause. Multi-omics approaches have been used to study the molecular mechanisms of preeclampsia, and various genetic variants, altered gene expressions, potential biomarkers, and metabolic changes have been identified. Microbiomics studies have also found dysbiosis in the microbiota of pregnant women with preeclampsia. Further research is needed to integrate and translate these findings into clinical practice.
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY
(2024)
